References
- Molina EJ, Shah P, Kiernan MS, Cornwell WK, Copeland H, Takeda K, Fernandez FG, Badhwar V, Habib RH, Jacobs JP et al. The Society of Thoracic Surgeons Intermacs 2020 Annual Report. Ann Thorac Surg. 2021; 111(3): 778–92.
- Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Färber G, Hannan MM, Kukucka M, de Jonge N, Loforte A, Lund LH et al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg. 2019; 56(2): 230–70.
- Goldstein DJ, Aaronson KD, Tatooles AJ, Silvestry SC, Jeevanandam V, Gordon R, Hathaway DR, Najarian KB, Slaughter MS. Gastrointestinal bleeding in recipients of the HeartWare Ventricular Assist System. JACC Heart Fail. 2015; 3(4): 303–13.
- Ben Gal T, Ben Avraham B, Milicic D, Crespo-Leiro MG, Coats AJS, Rosano G, Seferovic P, Ruschitzka F, Metra M, Anker S et al. Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. Eur J Heart Fail. 2021; 23(10): 1597–609.
- Ząbczyk M, Majewski J, Lelakowski J. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation. Pol Arch Intern Med. 2011; 121(11): 400–407.
- Piróg M, Piwowarczyk S, Undas A. Plasma Fibrin Clot Properties Are Unfavorably Altered in Women following Venous Thromboembolism Associated with Combined Hormonal Contraception. Dis Markers. 2019 Nov 18; 2019: 4923535.
- Leander K, Blombäck M, Wallén H, He S. Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction. Thromb Haemost. 2012; 107(6): 1092–9.
- Konieczynska M, Fil K, Bazanek M, Undas A. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Thromb Haemost. 2014; 111(4): 685–93.
- Mazur P, Ząbczyk M, Khan I, Litwinowicz R, Iwaniec T, Kędziora A, Kapelak B, Natorska J. Fibrin clot susceptibility to lysis is impaired after on-pump coronary artery by-pass grafting with tranexamic acid: clinical implications. Blood Coagul Fibrinolysis. 2021; 32(1): 29.
- Kirklin JK, Pagani FD, Goldstein DJ, John R, Rogers JG, Atluri P, Arabia FA, Cheung A, Holman W, Hoopes C et al. American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support. J Thorac Cardiovasc Surg. 2020; 159(3): 865–96.
- Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summary. J Heart Lung Transplant. 2013; 32(2): 157–87.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [Internet]. [cited 2022 Jan 6]. Available from:
https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure ,https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Acute-and-Chronic-Heart-Failure - Ząbczyk M, Natorska J, Janion-Sadowska A, Metzgier-Gumiela A, Polak M, Plens K, Janion M, Skonieczny G, Mizia-Stec K, Undas A. Prothrombotic fibrin clot properties associated with NETs formation characterize acute pulmonary embolism patients with higher mortality risk. Sci Rep. 2020; 10(1): 11433.
- Loforte A, Botta L, Boschi S, Gliozzi G, Cavalli GG, Mariani C, Suarez SM, Pacini D. Durable Continuous-Flow Mechanical Circulatory Support: State of the Art. Hearts. 2021; 2(1): 127–38.
- Kramser N, Oehler D, Saeed D, Aubin H, Akhyari P, Kelm M, Westenfeld R, Horn P. Thromboembolic Events in Patients With Left Ventricular Assist Devices Are Related to Microparticle-Induced Coagulation. ASAIO J. 2021; 67(1): 59.
- Kuczaj A, Hudzik B, Kaczmarski J, Przybyłowski P. Hemostasis Disturbances in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients—Rationale and Study Design. J Clin Med. 2022; 11(13): 3712.
- Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4): 692–4.
- Bazan-Socha S, Kuczia P, Potaczek DP, Mastalerz L, Cybulska A, Zareba L, Kremers R, Hemker C, Undas A. Increased blood levels of cellular fibronectin in asthma: Relation to the asthma severity, inflammation, and prothrombotic blood alterations. Respir Med. 2018; 141: 64–71.
- Cellai AP, Lami D, Magi A, Liotta AA, Rogolino A, Antonucci E, Bandinelli B, Abbate R, Prisco D. Assessment of Fibrinolytic Activity by Measuring the Lysis Time of a Tissue Factor-induced Clot: A Feasibility Evaluation. Clin Appl Thromb. 2010; 16(3): 337–44.
- Mazur P, Natorska J, Sobczyk D, Gawęda B, Bartuś K, Filip G, Kapelak B, Undas A. Plasma fibrin clot properties affect blood loss after surgical aortic valve replacement for aortic stenosis. Eur J Cardiothorac Surg. 2019; 55(2): 224–31.
- Ząbczyk M, Majewski J, Lelakowski J. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation. Pol Arch Intern Med. 2011; 121(11): 400–7.
- Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, Himmelmann A, Ajjan RA, Storey RF. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J. 2018; 39(13): 1078–85.
- Jaworska-Wilczyńska M, Natorska J, Siudut J, Marzec K, Kowalik I, Hryniewiecki T, Undas A. Patients scheduled for TAVI tend to form abnormal fibrin clots more resistant to lysis: the impact of age. Kardiologia Pol Pol Heart J. 2021; 79(7–8): 796–803.
- Carter AM, Cymbalista CM, Spector TD, Grant PJ. Heritability of Clot Formation, Morphology, and Lysis. Arterioscler Thromb Vasc Biol. 2007; 27(12): 2783–9.